Parkinson's disease: recent advances in therapy.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000313:Adrenal Medulla / Q000637:transplantation; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004298:Dopamine / Q000172:deficiency; D004334:Drug Administration Schedule; D004338:Drug Combinations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000175:diagnosis; D011725:Pyridines / Q000009:adverse effects
D000978:Antiparkinson Agents; D004338:Drug Combinations; D011725:Pyridines; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D002230:Carbidopa; D004298:Dopamine